ArticleBMC gastroenterology2026
Corticosteroid use, bone density screening, and the influence of insurance in patients with inflammatory bowel disease: a retrospective analysis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorticosteroid use among inflammatory bowel disease (IBD) patients is common as they are highly effective in the management of flares. However, both corticosteroid use and IBD have been linked to bone mineral density deficiencies. As a result, guidelines recommend dual-energy X-ray absorptiometry (DEXA) screening in these patients. The main objectives of this study were threefold: to quantify the amount of corticosteroids prescribed per patient, assess whether patients were appropriately referred for DEXA scans according to Centers for Medicare and Medicaid Services (CMS) guidelines, and to evaluate the rate of completion for the ordered DEXA scans. Additionally, we aimed to evaluate whether insurance status impacted the cumulative amounts of corticosteroids prescribed and access to DEXA scans.
methodsSixteen thousand, three hundred eighty-seven adult patients who were seen at two tertiary healthcare systems in the southeastern United States with a diagnosis of IBD were included. Patient characteristics and DEXA scan referral rates were obtained. Patients prescribed ≥ 600 prednisone equivalents were deemed to qualify for DEXA scan screening.
resultsUnderinsured patients (UP) were prescribed significantly more prednisone and less budesonide than insured patients (IP). There was no significant difference in scan completion rate: 66.7% for UP and 75.6% for IP. Overall, the completion rates for DEXA scans among patients prescribed ≥ 600 equivalents were 19.6% for UP and 20.3% for IP, with an overall rate of 20.3%.
conclusionDEXA scan screening for bone mineralization deficits is underperformed for IBD patients on chronic steroid therapy. Insurance had no impact on the ordering or completion rate of DEXA scans in our study.
trial registrationRetrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.